Currently, I am doing a doctoral thesis entitled Genetic Algorithms Applied to Translational Strategy in NASH. Learning from Mouse Models in which I apply 🧬 genetic algorithms 🧬 for the selection of NAFLD subtypes. This procedure could be applied to any disease that is based on metabolic changes. This work also has implications in the field of precision medicine.

• 📚 ORCID
• 📚 Scopus
• 📚 pubmed

'Omics' research generates a large amount of data for every sample. OWL has established a well-defined workflow and a set of guidelines for analyzing omics data. It includes statistical design of experiments, data structuration and predictive modelling.

Peer-reviewed papers:

1. Martínez-Arranz, I, et al. Enhancing metabolomics research through data mining, J. Proteomics, 2015;127(B)275-288.
2. Barr J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J. Proteome Res 2012;11(4),2521-32
3. Arbelaiz A, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017; 10.1002/hep.29291.
4. Cano A, et al. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Scientific Reports. 2017;7(1):10497.

We have developed predictive algorithms for several diseases. We have been really involved in the development and validation of the OWLiver, OWLiver F2+ and OWLiver DM2 tests.

Peer-reviewed papers:

1. Barr J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J. Proteome Res. 2012;11(4):2521-32.
2. Cano A, et al. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Scientific Reports. 2017;7(1):10497.
3. Herreros-Villanueva M, et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clin Transl Gastroenterol. 2019 Jan;10(1).
4. Matorras R, et al. The lipidome of endometrial fluid differs between implantative and non-implantative IVF cycles. J Assist Reprod Genet. 2020;37(2):385-94.
5. Martínez-Arranz I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun. 2018 May 4;2(7):807-820.

Peer-reviewed papers:

1. Alonso C, et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology 2017;152(6):1449-61.
2. Iruarrizaga-Lejarreta M, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatology Communications 2017;1(9):911-27.
3. Banales JM, et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Hepatology 2019;70(2):547-65.
4. Herreros-Villanueva M, et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clin Transl Gastroenterol. 2019 Jan;10(1).
5. Matorras R, et al. The lipidome of endometrial fluid differs between implantative and non-implantative IVF cycles. J Assist Reprod Genet. 2020;37(2):385-94.

🟨 NAFLD Disease 🟩 Subtypes 🟧 Machine Learning and Modelling 🟪 In Vitro Diagnostic test

ARTICLE	DOI	PURPOSE
Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF)		🟨🟧🟪
Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy. (2023)		🟧
Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. (2022)		🟨🟩🟧
A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. (2020)		🟧
Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. (2020)		🟨
CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. (2020)		🟧
The lipidome of endometrial fluid differs between implantative and non-implantative IVF cycles. (2020)		🟧
Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. (2019)		🟨🟧🟪
Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. (2019)		🟧
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. (2019)		🟧
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. (2019)		🟧
Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. (2018)		🟩
Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. (2018)		🟧
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. (2018)		🟨🟧🟪
Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. (2018)		🟨🟧🟪
Role of Aramchol in steatohepatitis and fibrosis in mice. (2017)		🟨🟩🟧
A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. (2017)		🟧
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. (2017)		🟨🟩🟧
Data in support of enhancing metabolomics research through data mining. (2015)		🟧
Enhancing metabolomics research through data mining. (2015)		🟧
Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. (2013)		🟧
Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. (2013)		🟧
Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression. (2012)		🟨🟧